<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165617</url>
  </required_header>
  <id_info>
    <org_study_id>V130_12</org_study_id>
    <secondary_id>2016-002883-15</secondary_id>
    <nct_id>NCT03165617</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to &lt;18 Years of Age</brief_title>
  <official_title>A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Influenza Comparator Vaccine in Subjects ≥2 to &lt;18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized, observer-blind non-influenza comparator controlled study is intended to
      demonstrate the efficacy, immunogenicity, safety and tolerability of Seqirus' cell-based
      inactivated quadrivalent vaccine (QIVc) in subjects ≥2 years to &lt;18 years of age
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) or culture confirmed influenza, due to any influenza Type A and B strain in subjects ≥2 years to &lt;18 years of age</measure>
    <time_frame>Day 14 to Day 180 or until the end of the influenza season, whichever is longer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence RT-PCR or culture confirmed influenza, due to any influenza Type A and B strain in subjects ≥3 years to &lt;18 years of age</measure>
    <time_frame>Day 14 to Day 180 or until the end of the influenza season, whichever is longer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence RT-PCR or culture confirmed influenza, due to any influenza Type A and B strain by age subgroup</measure>
    <time_frame>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Absolute vaccine efficacy of QIVc by first occurrence culture confirmed influenza, caused by influenza strains antigenically matched to the strains selected for the seasonal vaccine</measure>
    <time_frame>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Absolute vaccine efficacy of QIVc determined by first occurrence RT-PCR influenza, due to any influenza Type A and B strain</measure>
    <time_frame>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Absolute vaccine efficacy of QIVc determined by first occurrence culture confirmed influenza, due to any influenza Type A and B strain</measure>
    <time_frame>Day 14 to Day 180 or until the end of the influenza season, whichever is longer.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Hemagglutination Inhibition (HI) Geometric mean titers (GMTs)</measure>
    <time_frame>Day 1 (all subjects), Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Percentage of subjects achieving seroconversion (seroconversion rate) for all 4 influenza strains</measure>
    <time_frame>Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: HI Geometric Mean Ratio (GMR)</measure>
    <time_frame>Day 22/Day 1 (all previously vaccinated subjects) or Day 29/Day 1 and Day 50/Day 1 (all not previously vaccinated subjects)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Percentage of subjects with HI titer ≥ 1:40</measure>
    <time_frame>Day 22 (all previously vaccinated subjects) or Day 29 and Day 50 (all not previously vaccinated subjects)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: The percentage of subjects with solicited local adverse events (AE)</measure>
    <time_frame>Day 1 to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: The percentage of subjects with solicited systemic AEs</measure>
    <time_frame>Day 1 to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: The percentage of subjects with all unsolicited AEs</measure>
    <time_frame>Day 1 to Day 22 (for previously vaccinated subjects) or Day 1 to Day 50 (for not previously vaccinated subjects)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Percentage of subjects with SAEs, AEs leading to withdrawal from the study and New Onset of Chronic Diseases (NOCD)</measure>
    <time_frame>Day 1 to Day 181 (for previously vaccinated subjects) or to Day 209 (for not previously vaccinated subjects)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Percentage of subjects with medically-attended AEs</measure>
    <time_frame>Within 30 days of first occurrence of RT-PCR confirmed influenza-like-illness (ILI)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7692</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>QIVc (≥2 years to &lt;18 Years of Age)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cell-derived Seasonal Quadrivalent Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Influenza Comparator Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-Influenza Comparator Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIVc</intervention_name>
    <description>Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains</description>
    <arm_group_label>QIVc (≥2 years to &lt;18 Years of Age)</arm_group_label>
    <other_name>Flucelvax Quadrivalent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-influenza Comparator Vaccine</intervention_name>
    <description>Non-influenza comparator vaccine for intramuscular use</description>
    <arm_group_label>Non-Influenza Comparator Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females ≥2 years to &lt;18 years of age

          -  Individual who or whose parent(s) or legal guardian have given informed consent
             /assent after the nature of the study has been explained according to local regulatory
             requirements, prior to study entry

          -  Ability to comply with study procedures and are available for follow-up

        Exclusion Criteria:

          -  Hypersensitivity, including allergy to any component of vaccines foreseen in this
             study

          -  Abnormal function of the immune system

          -  Receipt of any influenza vaccine within 6 months prior to enrolment in this study or
             who plan to receive influenza vaccine while participating in the study.

          -  Pregnant or breastfeeding individual

          -  Female subject of childbearing potential, sexually active, and not used an acceptable
             method of birth control for at least 2 months prior to study entry and intend to use
             until the end of subject participation

        Additional eligibility criteria may be discussed by contacting the site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Physician</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AusTrials Pty Ltd</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merekivi Family Doctors Ltd</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merelahe Family Doctors Centre</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicum AS</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vee Family Doctors Centre</name>
      <address>
        <city>Paide</city>
        <state>Järvamaa</state>
        <zip>72713</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Dasmarinas</city>
        <state>Cavite</state>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <state>National Capital Region</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute For Tropical Medicine</name>
      <address>
        <city>Muntinlupa</city>
        <state>National Capital Region</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <state>Muang</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChiangMai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

